GC Biopharma’s groundbreaking for the plasma fractionation plant in Indonesia
GC Biopharma, a South Korean biopharmaceutical company, announced on December 6th that it has participated in the groundbreaking ceremony of a plasma fractionation plant held at Jababeka Industrial Estate in Indonesia, one of the company’s overseas plant construction projects. Backed by the Indonesian…
PharmAbcine Publishes Study in Science Advances Demonstrating the Potential of PMC-403 in Preclinical Models of Idiopathic Systemic Capillary Leak Syndrome
PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announces the publication of preclinical research in Science Advances, highlighting the potential of its Tie2-activating antibody program, PMC-403, in treating Idiopathic Systemic Capillary Leak…
Intake Health Introduces New Hydration Testing Tech to Pro Sports
Intake Health, a health technology company with cutting edge health monitoring research funded by both the National Science Foundation (NSF) and National Institute of Health (NIH), has made waves across sports in North America since officially launching it’s InFlow hydration testing solution…
Africa CDC Director General Visits SK bioscience to Discuss Vaccine Localization in Africa
SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that H.E Dr. Jean Kaseya, Director General of Africa CDC visited SK bioscience headquarters on November 3 to discuss collaboration with the Partnerships for African…
Oncoclínicas opens first Cancer Center in Brazil as an International Collaborative Member of Dana-Farber Cancer Institute
Oncoclínicas&Co, the largest group dedicated to cancer in Latin America, and Dana-Farber Cancer Institute, a Harvard Medical School affiliated teaching hospital and one of the world’s leading cancer treatment and oncology research institutions, announce the expansion of their collaboration with the opening of…
Esteemed Plastic Surgeon Dr. Mariotti and Cosmetic Physician Partners (CPP) Unite to Shape the Future of Aesthetic Medicine
Prominent plastic surgeon Dr. Eric Mariotti is excited to announce a transformative partnership with Cosmetic Physician Partners (CPP). This collaboration reflects Dr. Mariotti’s commitment to patient well-being, innovative practices, and the long-term growth of his practice. The decision to join forces…
Medline recognizes SHARE Cancer Support as its first Pink Glove Grant recipient
Medline today announced SHARE Cancer Support as the recipient of its first-ever Pink Glove Grant. SHARE will receive a $25,000 grant from the Medline Foundation to help fund their program and expand breast cancer awareness within the Hispanic community. Across the nation, health outcomes…
NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the Treatment of Chronic Pain
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company today announced further alignment with the FDA Division of Anesthesiology, Addiction Medicine, and Pain Medicine in connection with the development of NRX-101 for treatment of Chronic Pain. The…
Hartford HealthCare and Walgreens partner to provide health clinics that improve access to care
Walgreens and Hartford HealthCare will add health clinics to select Walgreens locations in Connecticut, advancing a unique retail health model based on convenience, access to care, affordability and health equity. This is Walgreens first retail clinic collaboration with a health system…
AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS VECTIBIX® (PANITUMUMAB) DATA IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
Amgen (NASDAQ:AMGN) today announced data from the global Phase 3 CodeBreaK 300 trial evaluating two doses of LUMAKRAS® (sotorasib) (960 mg or 240 mg) in combination with Vectibix® (panitumumab). Both doses demonstrated a statistically significant superiority in progression-free survival (PFS) over the investigator’s choice of…
